Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harmony Biosciences Holdings, Inc.

29.44
+0.08000.27%
Post-market: 29.440.00000.00%16:26 EDT
Volume:415.04K
Turnover:12.23M
Market Cap:1.69B
PE:11.73
High:29.71
Open:29.44
Low:28.92
Close:29.36
Loading ...

Harmony Biosciences' Q4 Adjusted Earnings, Net Product Revenue Rise

MT Newswires Live
·
25 Feb

Earnings Flash (HRMY) Harmony Biosciences Posts Q4 Net Product Revenue $201.3M, vs. FactSet Est of $201M

MT Newswires Live
·
25 Feb

Harmony Biosciences Q4 Adj $1.08 Beats $0.74 Estimate, Sales $201.27M Beat $201.25M Estimate

Benzinga
·
25 Feb

BRIEF-Harmony Biosciences Q4 Net Income USD 49.475 Million

Reuters
·
25 Feb

Harmony Biosciences: Reiterates 2025 Net Revenue Guidance

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Q4 Operating Income USD 55.727 Million

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Qtrly Adj EPS $1.08

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Holdings Inc Q4 Shr View $0.74, REV View $201.0 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Qtrly Net Product Revenues $201.3 Million

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Holdings Inc FY2025 REV View $848.5 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

Business Wire
·
25 Feb

Is Harmony Biosciences (HRMY) the Oversold Biotech Stock to Buy Now?

Insider Monkey
·
25 Feb

Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why

Zacks
·
25 Feb

5 High Earnings Yield Value Stocks to Buy Amid Market Volatility

Zacks
·
24 Feb

Harmony Biosciences Holdings Inc expected to post earnings of 74 cents a share - Earnings Preview

Reuters
·
21 Feb

Mizuho Adjusts Price Target on Harmony Biosciences to $42 From $52, Keeps Outperform Rating

MT Newswires Live
·
20 Feb

Harmony Biosciences Holdings, Inc. : Deutsche Bank Cuts Target Price to $52 From $55

THOMSON REUTERS
·
20 Feb

Concerns Over Harmony Biosciences: FDA Setback, Patent Risks, and High-Risk Pipeline

TIPRANKS
·
20 Feb

Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

Benzinga
·
20 Feb

Harmony Biosciences Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb